The board of directors of Quest Diagnostics (NYSE:DGX) approved a quarterly dividend of USD0.53 per share of the company's common stock, it declared on Friday.
Shareholders of record of common stock as of 8 April 2019 will receive the dividend on 22 April 2019.
Quest Diagnostics said it empowers people to take action to improve health outcomes and annually serves one in three adult Americans, as well as half the physicians and hospitals in the US.
Derived from the world's largest database of clinical lab results, the company's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviours and improve health care management.
ValiRx subsidiary Inaphaea extends drug repurposing deal with Dominion Biotech
Lilly declares Q2 2025 dividend
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Emmaus Life Sciences reports drop in revenues, increased loss in 2024
L'Oréal and WHO Foundation partner to expand global skin health access
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
ANI Pharmaceuticals announces buyout of royalty obligation for ILUVIEN and YUTIQ
Sirum collaborates with Governor Wes Moore to expand medication access across Maryland